Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with L265P mutation.
作者信息
Dlouhy Ivan, Armengol Marc, Recasens-Zorzo Clara, Ribeiro Marcelo L, Pérez-Galán Patricia, Bosch Francesc, López-Guillermo Armando, Roué Gaël
机构信息
Department of Hematology, Hospital Clínic, BarceIona, Spain; Division of Hematology and Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona.
Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona.
出版信息
Haematologica. 2021 Oct 1;106(10):2749-2753. doi: 10.3324/haematol.2020.278258.
Abstract
摘要
相似文献
1
Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with L265P mutation.
Haematologica. 2021 Oct 1;106(10):2749-2753. doi: 10.3324/haematol.2020.278258.
2
Oncogenically active MYD88 mutations in human lymphoma.
Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.
3
Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with L265P mutation.
Haematologica. 2022 Dec 1;107(12):2990. doi: 10.3324/haematol.2022.281988.
4
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Blood. 2013 Aug 15;122(7):1222-32. doi: 10.1182/blood-2012-12-475111. Epub 2013 Jul 8.
5
Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
Int J Mol Sci. 2023 Mar 15;24(6):5623. doi: 10.3390/ijms24065623.
6
Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
J Virol. 2020 May 4;94(10). doi: 10.1128/JVI.02123-19.
7
HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Blood. 2018 Aug 2;132(5):510-520. doi: 10.1182/blood-2017-12-819706. Epub 2018 Jun 5.
8
Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
Oncol Rep. 2019 Nov;42(5):1755-1766. doi: 10.3892/or.2019.7282. Epub 2019 Aug 19.
9
Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Eur J Med Chem. 2020 Mar 15;190:112092. doi: 10.1016/j.ejmech.2020.112092. Epub 2020 Jan 25.
10
The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain.
Blood Cancer J. 2023 Aug 18;13(1):125. doi: 10.1038/s41408-023-00896-6.
引用本文的文献
1
YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2 germinal center-derived lymphoma.
Neoplasia. 2025 Mar;61:101131. doi: 10.1016/j.neo.2025.101131. Epub 2025 Feb 5.
2
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy.
Front Immunol. 2023 Apr 21;14:1130052. doi: 10.3389/fimmu.2023.1130052. eCollection 2023.
本文引用的文献
1
Molecular pathogenesis of germinal center-derived B cell lymphomas.
Immunol Rev. 2019 Mar;288(1):240-261. doi: 10.1111/imr.12745.
2
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30.
3
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Oncogene. 2018 Apr;37(14):1830-1844. doi: 10.1038/s41388-017-0111-1. Epub 2018 Jan 22.
4
High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
Leuk Res. 2017 Aug;59:20-25. doi: 10.1016/j.leukres.2017.05.014. Epub 2017 May 17.
5
Treatment of Diffuse Large B-Cell Lymphoma.
J Clin Exp Hematop. 2016;56(2):79-88. doi: 10.3960/jslrt.56.79.
6
B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
Blood. 2016 Jun 2;127(22):2732-41. doi: 10.1182/blood-2015-11-684183. Epub 2016 Apr 5.
7
MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
Clin Cancer Res. 2016 Jun 1;22(11):2755-64. doi: 10.1158/1078-0432.CCR-15-1525. Epub 2016 Jan 20.
8
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
J Exp Med. 2015 Dec 14;212(13):2189-201. doi: 10.1084/jem.20151074. Epub 2015 Nov 30.
9
Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4.
Bioorg Med Chem Lett. 2015 Dec 1;25(23):5546-50. doi: 10.1016/j.bmcl.2015.10.060. Epub 2015 Oct 23.
10
Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.
J Clin Invest. 2015 Mar 2;125(3):1081-97. doi: 10.1172/JCI75821. Epub 2015 Feb 2.
Zotero 插件